Moody's Sees Potential Pfizer/Allergan Deal as Credit-Positive Development (PFE) (AGN)
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $28.41 +0.82%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.6%
Join SI Premium – FREE
Moody's Investors Service commented that the potential combination of Pfizer Inc. and Allergan Plc would have credit positive implications for both companies. The companies have confirmed friendly discussions, but no deal has been reached and there is currently no impact to the ratings of either company. Pfizer is rated A1 with a stable outlook and Allergan's rated subsidiaries, including Allergan, Inc., are rated Baa3 with a stable outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades TotalEnergies SE (TTE:FP) (TTE) to Buy
- Chevron (CVX) PT Raised to $250 at HSBC
- Goldman Sachs Upgrades Alsea SAB de CV (ALSEA:MM) (ALSSF) to Neutral
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors ServiceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
